Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients

類似資料

• Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
  著者:: Ohar, Jill A, 等
  出版事項: (2014)
• The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
  著者:: Yawn, Barbara P, 等
  出版事項: (2010)
• Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
  著者:: Dalal, Anand A, 等
  出版事項: (2012)
• Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
  著者:: Dalal, Anand A, 等
  出版事項: (2011)
• Effect of fluticasone 250 μg/salmeterol 50 μg and montelukast on exhaled nitric oxide in asthmatic patients
  著者:: Gelb, Arthur F, 等
  出版事項: (2008)